

February 19, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 19, 2026, titled **“Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care

ANYRA™ is India's first indigenously developed Aflibercept 2 mg biosimilar

Ahmedabad, India, 19 February, 2026

Zydus Lifesciences Ltd., an innovation-led global life sciences company, today announced the launch of Anyra™, India's first indigenously developed biosimilar of Aflibercept 2 mg. Zydus has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer. Anyra™ is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV). With this launch, Zydus reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.

Presently, more than 100 million people in India are living with diabetes, making it one of the largest diabetic populations globally. Diabetic Retinopathy (DR) affects an estimated 7–8 million individuals, with many progressing to vision-threatening stages such as DME. Wet AMD impacts approximately 1.5–2 million elderly patients, while Retinal Vein Occlusions affect over 2 million individuals. Collectively, these conditions represent a large patient pool requiring timely anti-VEGF therapy to prevent irreversible vision loss. As chronic retinal diseases require repeated intravitreal injections over extended periods, affordability and continuity of treatment are of concern. Enhanced access to such therapies improves treatment adherence, reduces preventable blindness, and lowers long-term disease burden.

Speaking on the launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said, “At Zydus, we are committed to making advanced biologics accessible to patients who need them most. ANYRA™ is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics. Our focus remains on enabling patient-centric outcomes by leveraging science, health and innovation.”

Zydus has India's largest biosimilar portfolio with more than 13 biosimilars and complex biologic molecules developed and manufactured entirely in India. The company has established end-to-end capabilities across biologics development - from cell line research and process engineering to clinical trials, manufacturing, and regulatory approvals.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

About Zydus Lifesciences Limited

Zydus Lifesciences Limited is an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a strong international presence across the United States, India, and other global markets. As of September 30, 2025, the group employs approximately 29,000 people worldwide, including 1,500 scientists engaged in research and development. The company is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

For more details, please visit: www.zyduslife.com

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878